3. Update on other contracts in
/ discussions with other companies
J&J and Curevac - work progresses well. The signature of the two contracts will, most
probably, take place in the coming weeks.
Moderna – the issue linked to
is
to continue with the process.
BioNTech- the
was to be constituted in the next days.
Novavax – the Member of the SB were informed about the latest moves
the exploratory discussions were finalized, leaving the next steps up to the
MS’s political decision.
Valneva - the Members were informed on discussions regarding several aspects of the
possible offer with a request to be clear on the doses each Member State would want.
4. Strategic discussion about expanding the current portfolio of 6+1
A number of MSs
pleaded for a broader Portfolio and for the continuation
of discussions and possible negotiations with companies beyond the 6+1.
The
the Members to reflect on how to approach strategically a
future expansion of the current portfolio and proposed to discuss the issue at the next
meetings of the Steering Board.
5. Details necessary for planning of logistics in the implementation of contracts
The Commission asked companies to provide information on characteristics of each vaccine,
which would be shared with the Member States.
The Commission also underlined that coordination with the Health Security Committee
needed to be ensured, in the context in which MSs needed to order the material necessary to
run vaccination campaigns.
A joint procurement procedure on the supply of medical equipment for COVID-19
vaccination should be launched in the coming days.
6. COVAX
In a separate meeting, dedicated to COVAX, the European Commission informed on:
• its participation in the COVAX Facility for equitable access to affordable COVID-19
vaccines, following its expression of interest on 31 August and its announcement of a
contribution
;